The study is sponsored by the national institute of allergy and infectious diseases (niaid). This compares to loss of $0.03 per share a year ago.
On average, they expect matinas biopharma's stock price to reach $3.33 in the next year.
Mtnb stock forecast zacks. 93 rows mtnb earnings information. Strong buy stocks for december, 2021. Nyse updated nov 29, 2021 9:00 pm.
This suggests a possible upside of 270.4% from the stock's current price. Mtnb) has announced positive data from the first two cohorts of the phase 2 enact trial of mat2203 (oral amphotericin b) for cryptococcal meningitis. (mtnb) came out with a quarterly loss of $0.03 per share in line with the zacks consensus estimate.
The average price target is $3.00 with a high forecast of $3.00 and a low forecast of $3.00. This upgrade primarily reflects an upward trend in earnings. By zacks equity research published on may 10,2021.
The prediction is based on 5 analyst estimates. The average price target represents a 275.00% change from the last price of $0.80. (mtnb) could be a solid addition to your portfolio given its recent upgrade to a zacks rank #2 (buy).
What is mtnb stock forecast (i.e., prediction)? That means the average analyst price target for mtnb stock is $2.38. (mtnb) reports q1 loss, misses revenue estimates.
(mtnb) came out with a quarterly loss of $0.03 per share in line with the zacks consensus estimate. Analyst price target on mtnb. Matinas biopharma last released its.
Mtnb matinas biopharma holdings inc. Mtnb | complete matinas biopharma holdings inc. (mtnb) could be a solid addition to your portfolio given its recent upgrade to a zacks rank #2 (buy).
Based on mtnb analyst price targets, mtnb stock forecast is $2.38 (for a year from now). This compares to zero revenues a year ago. Their forecasts range from $3.00 to $4.00.
This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. Based on 3 wall street analysts offering 12 month price targets for matinas biopharma in the last 3 months. Matinas biopharma stock jumps after meningitis candidate data.
Mtnb 1.02 0.07 (6.42%) 11,225. — stock price and discussion | stocktwits. Matinas biopharma holdings inc (nyse:
The sole determinant of the zacks rating is a company's changing earnings. The low price target for mtnb is $0.90, while the high price target is $3.00.
